Formulation: A solid
Formal Name: (6aR,9R)-5-bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-8H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-(methyl-13C-d3)-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
Purity: ≥99% deuterated forms (d1-d3)
Formula Markup: C31[13C]H37D3BrN5O5
Formula Weight: 658,6
Shelf life (days): 1460
Notes: Bromocriptine-13C-d3 is intended for use as an internal standard for the quantification of bromocriptine (Item No. 14598) by GC- or LC-MS. Bromocriptine is a dopamine receptor agonist (Kis = 1,659, 12.2, 12.2, 59.7, and 1,691 nM for dopamine D1, D2, D3, D4, and D5 receptors, respectively).{21784} It also binds to the serotonin (5-HT) receptor subtypes 5-HT1A and 5-HT1D (Kis = 12.9 and 10.7 nM, respectively), as well as α1-adrenergic receptors (Kis = 1.12-4.17 nM).{21784,21785} Bromocriptine (5 mg/kg) restores locomotor activity, without inducing dyskinesia, in a macaque model of Parkinson’s disease induced by MPTP.{53230} Formulations containing bromocriptine have been used in the treatment of Parkinson's disease, hyperprolactinemia-associated dysfunctions, and acromegaly.
English
Deutsch
